Research area

Dermal research

Compounds studied in dermal research research: what each trial measured, and links to the sources.

GHK-Cu

Clinical evidence

Strong, repeated clinical trial evidence for skin and wound healing (see Healing & recovery); smaller human trials also show real improvements in hair count and follicle density with topical use, resting on smaller trials than the skin evidence.

For skin: see the full GHK-Cu entry under Healing & recovery. The scar-reduction, wound-closure and collagen-increase trials there apply directly to the skin and aesthetic use case, extending beyond wound repair to collagen stimulation and visible skin quality. For hair specifically the evidence is real and thinner: a 2016 RCT using a GHK peptide formulation found significant hair-count increases after 6 months of topical use vs. placebo in men with pattern hair loss, and a 2015 study combining GHK-Cu with other hair-active peptides outperformed placebo on follicle density and diameter. The mechanism (VEGF upregulation, TGF-β1 suppression, Wnt/β-catenin activation in dermal papilla cells) is well-characterized in lab research. Honest summary: a well-understood mechanism, positive animal data, and a cluster of smaller positive human studies. Large-scale RCTs remain to be run.

Sources

GLOW (GHK-Cu + TB-500 + BPC-157)

Community evidence

A blend built from individually-researched compounds. Evidence exists for each ingredient on its own; the combination as a whole remains to be trialed.

A combination product (GHK-Cu + TB-500 + BPC-157) built from individually-researched compounds; see each one's own entry (GHK-Cu here and under Healing & recovery; BPC-157 and TB-500 under Healing & recovery). This specific combination remains to be trialed as a whole, the same caveat as the CJC-1295+Ipamorelin stack under Physical performance. Confidence in the individual ingredients applies to those ingredients: combining compounds can change absorption, interaction effects and outcomes in ways individual-ingredient trials leave open.

KLOW (GHK-Cu + BPC-157 + TB-500 + KPV)

Community evidence

A blend built from individually-researched compounds. Evidence exists for each ingredient on its own; the combination as a whole remains to be trialed.

A combination product (GHK-Cu + BPC-157 + TB-500 + KPV) built from individually-researched compounds; see each one's own entry (GHK-Cu here and under Healing & recovery; BPC-157, TB-500 and KPV under Healing & recovery). This specific combination remains to be trialed as a whole, the same caveat as the CJC-1295+Ipamorelin stack under Physical performance. Confidence in the individual ingredients applies to those ingredients: combining compounds can change absorption, interaction effects and outcomes in ways individual-ingredient trials leave open.

This is a summary of published and preclinical research, not medical advice. Every entry describes what a study found, not what you should do. These compounds are supplied for laboratory research only.

All research areas